The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic

References

• McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell Microbiol 2001;3:1–11.
   PubMed Web of Science ®Google Scholar
• Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008;10:37–54.
   PubMed Web of Science ®Google Scholar
• Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;360:512–19.
   Web of Science ®Google Scholar
• Ouwehand AC, Vaughan EE. Gastrointestinal microbiology. New York: Taylor & Francis. 2006.
   Google Scholar
• Rambaud JC, Buts JP, Corthier G, Flourie B. Gut microflora – digestive physiology and pathology. Paris: John Libbey Eurotext. 2006.
   Google Scholar
• Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol 2008;16:107–14.
   PubMed Web of Science ®Google Scholar
• Yan F, Polk DB. Commensal bacteria in the gut: learning who our friends are. Curr Opin Gastroenterol 2004;20:565–71.
   PubMed Web of Science ®Google Scholar
• Chichlowski M, Hale LP. Bacterial–mucosal interactions in inflammatory bowel disease – an alliance gone bad. Am J Physiol Gastrointest Liver Physiol 2008;295:G1139–49.
   PubMed Web of Science ®Google Scholar
• Haenel H, Bendig J. Intestinal flora in health and disease. Prog Food Nutr Sci 1975;1:21–64.
   Google Scholar
• Mai V, Draganov PV. Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World J Gastroenterol 2009;15:81–5.
   PubMed Web of Science ®Google Scholar
• Savage DC. The ecological digestive system and its colonisation. Rev Sci Tech Off Int Epiz 1989;8:259–73.
   PubMedGoogle Scholar
• Schultz M, Schölmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis 2003;21:105–28.
   PubMed Web of Science ®Google Scholar
• Schulze J, Sonnenborn U. The role of the gut flora in inflammatory bowel diseases. Shimoyama T, Axon A, Lee A, Podolsky DK, O’Morain C. Helicobacter meets inflammatory bowel disease. Tokyo: Medical Tribune Inc. 2002. 393–417.
   Google Scholar
• Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century – a clinical super-challenge. N Engl J Med 2009;360:439–43.
   PubMed Web of Science ®Google Scholar
• Chadwick DJ, Goode J. Antibiotic resistance: origins, evolution, selection and spread. Ciba Foundation Symposium 207. Chichester: John Wiley & Sons. 1997.
   Google Scholar
• Davies J. Microbes have the last word. A drastic reevaluation of antimicrobial treatment is needed to overcome the threat of antibiotic-resistant bacteria. EMBO Rep 2007;8:616–21.
   Web of Science ®Google Scholar
• Hawkey PM. Action against antibiotic resistance: no time to lose. Lancet 1998;351:1298–9.
   PubMed Web of Science ®Google Scholar
• Witte W, Cuny C, Klare I, Nübel U, Strommenger B, Werner G. Emergence and spread of antibiotic-resistant gram-positive bacterial pathogens. Int J Med Microbiol 2008;298:365–77.
   PubMed Web of Science ®Google Scholar
• Schulze J, Sonnenborn U, Ölschläger T, Kruis W. Probiotika - Mikroökologie, Mikrobiologie, Qualität, Sicherheit und gesundheitliche Effekte. Stuttgart: Hippokrates/Thieme. 2008.
   Google Scholar
• Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol 2009;44:26–46.
   PubMed Web of Science ®Google Scholar
• Fric P. Probiotics in gastroenterology. Z Gastroenterol 2002;40:197–201.
   Web of Science ®Google Scholar
• Montrose DC, Floch MH. Probiotics used in human studies. J Clin Gastroenterol 2005;39:469–84.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 2005;21:44–50.
   PubMed Web of Science ®Google Scholar
• Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med 2005;257:78–92.
   PubMed Web of Science ®Google Scholar
• Tannock GW. Probiotics: time for a dose of realism. Curr Issues Intest Microbiol 2003;4:33–42.
   Google Scholar
• FAO/WHO. 2001. Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina, 1–4 October 2001.
   Google Scholar
• Vergin F. Anti- und Probiotika. Hippokrates 1954;25:116–9.
   PubMedGoogle Scholar
• Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science 1965;147:747–8.
   PubMed Web of Science ®Google Scholar
• Parker RB. Probiotics, the other half of the antibiotic story. Anim Nutr Health 1974;29:4–8.
   Google Scholar
• Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365–78.
   PubMedGoogle Scholar
• Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39:237–8.
   PubMed Web of Science ®Google Scholar
• Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996;275:870–6.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 1993;6:157–71.
   Web of Science ®Google Scholar
• Baumgart DC, Dignass AU. Current biological therapies for inflammatory bowel disease. Curr Pharm Des 2004;10:4127–47.
   Web of Science ®Google Scholar
• Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592–608.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366–73.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Rutgeerts P. Novel biological strategies in inflammatory bowel disease. Inflamm Bowel Dis 2004;10(Suppl 1):S44–51.
   Web of Science ®Google Scholar
• Bansal T, Garg S. Probiotics: from functional foods to pharmaceutical products. Curr Pharm Biotechnol 2008;9:267–87.
   PubMed Web of Science ®Google Scholar
• Bengmark S. Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics. Gastroenterol Clin North Am 2005;34:413–36.
   Web of Science ®Google Scholar
• Callaway TR, Edrington TS, Anderson RC, Harvey RB, Genovese KJ, Kennedy CN, . Probiotics, prebiotics and competitive exclusion for prophylaxis against bacterial disease. Anim Health Res Rev 2008;9:217–25.
   PubMedGoogle Scholar
• De Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008;111:1–66.
   PubMed Web of Science ®Google Scholar
• Marteau P. Living drugs for gastrointestinal diseases: the case for probiotics. Dig Dis 2006;24:137–47.
   Web of Science ®Google Scholar
• Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol 2008;606:423–54.
   PubMed Web of Science ®Google Scholar
• Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003;36:111–19.
   PubMed Web of Science ®Google Scholar
• Heselmans M, Reid G, Akkermans LM, Savelkoul H, Timmerman H, Rombouts FM. Gut flora in health and disease: potential role of probiotics. Curr Issues Intest Microbiol 2005;6:1–7.
   PubMedGoogle Scholar
• Reid G, Devillard E. Probiotics for mother and child. J Clin Gastroenterol 2004;38(Suppl 2):S94–101.
   Web of Science ®Google Scholar
• Schultz M. Clinical use of E. coli Nissle 1917 in inflamma-tory bowel disease. Inflamm Bowel Dis 2008;14:1012–18.
   PubMed Web of Science ®Google Scholar
• Nissle A. Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien. Med Klin 1918;2:29–33.
   Google Scholar
• Nissle A. Weiteres über Grundlagen und Praxis der Mutaflorbehandlung. Dtsch Med Wochenschr 1925;44:1809–13.
   Google Scholar
• Hamilton-Miller JMT. A review of clinical trials of probiotics in the management of inflammatory bowel disease. Infect Dis Rev 2001;3:83–7.
   Google Scholar
• Krammer HJ, Kämper H, Von Bünau R, Zieseniß E, Stange C, Schlieger F, . Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten. Z Gastroenterol 2006;44:651–6.
   PubMed Web of Science ®Google Scholar
• Kruis W. Antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(s4):75–8.
   Web of Science ®Google Scholar
• Blum-Oehler G, Oswald S, Eiteljörge K, Sonnenborn U, Schulze J, Kruis W, . Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol 2003;154:59–66.
   PubMed Web of Science ®Google Scholar
• Blum G, Marre R, Hacker J. Properties of Escherichia coli strains of serotype O6. Infection 1995;23:234–6.
   PubMed Web of Science ®Google Scholar
• Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, . A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002;184:5912–25.
   PubMed Web of Science ®Google Scholar
• Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, . Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 2004;186:5432–41.
   PubMed Web of Science ®Google Scholar
• Rietschel ET, Brade H, Holst O, Brade L, Müller-Loennies S, Mamat U, . Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Rietschel ET, Wagner H. Pathology of septic shock. Current Topics in Microbiology and Immunology, 216. Berlin: Springer-Verlag. 1996. 39–81.
   PubMed Web of Science ®Google Scholar
• Ott M, Bender L, Blum G, Schmittroth M, Achtman M, Tschäpe H, . Virulence patterns and long-range genetic mapping of extraintestinal Escherichia coli K1, K5, and K100 isolates: use of pulsed-field gel electrophoresis. Infect Immun 1991;59:2664–72.
   Web of Science ®Google Scholar
• Taylor PW. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev 1983;47:46–83.
   PubMedGoogle Scholar
• Hughes C, Phillips R, Roberts AP. Serum resistance among Escherichia coli strains causing urinary tract infection in relation to O type and the carriage of hemolysin, colicin, and antibiotic resistance determinants. Infect Immun 1982;35:270–5.
   Web of Science ®Google Scholar
• Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005;54:1182–93.
   PubMed Web of Science ®Google Scholar
• Wang Q, Suzuki A, Mariconda S, Porwollik S, Harshey RM. Sensing wetness: a new role for the bacterial flagellum. EMBO J 2005;24:2034–42.
   PubMed Web of Science ®Google Scholar
• Lasaro MA, Salinger N, Zhang J, Wang Y, Zhong Z, Goulian M, . F1C fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917. Appl Environ Microbiol 2009;75:246–51.
   PubMed Web of Science ®Google Scholar
• Stentebjerg-Olesen B, Chakraborty T, Klemm P. Type 1 fimbriation and phase switching in a natural Escherichia coli fimB null strain, Nissle 1917. J Bacteriol 1999;181:7470–8.
   PubMed Web of Science ®Google Scholar
• Hammar M, Arnqvist A, Bian Z, Olsen A, Normark S. Expression of two csg operons is required for production of fibronectin- and Congo red-binding curli polymers in Escherichia coli K-12. Mol Microbiol 1995;18:661–70.
   PubMed Web of Science ®Google Scholar
• Olsen A, Jonsson A, Normark S. Fibronectin binding mediated by a novel class of surface organelles on Escherichia coli. Nature 1989;338:652–5.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Dobrindt U, Hacker J, Hasnain SE. Genomic fluidity and pathogenic bacteria: applications in diagnostics, epidemiology and intervention. Nat Rev Microbiol 2008;6:387–94.
   PubMed Web of Science ®Google Scholar
• Hacker J, Kaper JB. Pathogenicity islands and the evolution of microbes. Annu Rev Microbiol 2000;54:641–79.
   PubMed Web of Science ®Google Scholar
• Hacker J, Carniel E. Ecological fitness, genomic islands and bacterial pathogenicity. A Darwinian view of the evolution of microbes. EMBO Rep 2001;2:376–81.
   PubMed Web of Science ®Google Scholar
• Hacker J, Hentschel U, Dobrindt U. Prokaryotic chromosomes and disease. Science 2003;301:790–3.
   Web of Science ®Google Scholar
• Große C, Scherer J, Koch D, Otto M, Taudte N, Grass G. A new ferrous iron-uptake transporter, EfeU (YcdN), from Escherichia coli. Mol Microbiol 2006;62:120–31.
   PubMed Web of Science ®Google Scholar
• Neilands JB. Mechanism and regulation of synthesis of aerobactin in Escherichia coli K12 (pColV-K30). Can J Micro-biol 1992;30:728–33.
   Web of Science ®Google Scholar
• Schubert S, Rakin A, Karch H, Carniel E, Heesemann J. Prevalence of the “high-pathogenicity island” of Yersinia species among Escherichia coli strains that are pathogenic to humans. Infect Immun 1998;66:480–5.
   PubMed Web of Science ®Google Scholar
• Schubert S, Rakin A, Fischer D, Sorsa J, Heesemann J. Characterization of the integration site of Yersinia high-pathogenicity island in Escherichia coli. FEMS Microbiol Lett 1999;179:409–14.
   Web of Science ®Google Scholar
• Torres AG, Payne SM. Haem iron-transport system in enterohemorrhagic Escherichia coli O157:H7. Mol Micro-biol 1997;23:825–33.
   PubMed Web of Science ®Google Scholar
• Azpiroz MF, Rodriguez E, Lavina M. The structure, function, and origin of the microcin H47 ATP- binding cassette exporter indicate its relatedness to that of colicin V. Antimicrob Agents Chemother 2001;45:969–72.
   Web of Science ®Google Scholar
• Gaggero C, Moreno F, Lavina M. Genetic analysis of microcin H47 antibiotic system. J Bacteriol 1993;175:5420–7.
   Web of Science ®Google Scholar
• Rodriguez E, Gaggero C, Lavina M. The structural gene for microcin H47 encodes a peptide precursor with antibiotic activity. Antimicrob Agents Chemother 1999;43:2176–82.
   PubMed Web of Science ®Google Scholar
• Patzer SI, Baquero MR, Bravo D, Moreno F, Hantke K. The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 2003;149:2557–70.
   PubMed Web of Science ®Google Scholar
• Homburg S, Oswald E, Hacker J, Dobrindt U. Expression analysis of the colibactin gene cluster coding for a novel polyketide in Escherichia coli. FEMS Microbiol Lett 2007;275:255–62.
   PubMed Web of Science ®Google Scholar
• Nougayrede JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, . Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006;313:848–51.
   PubMed Web of Science ®Google Scholar
• Zijlstra JB, Beukema J, Wolthers BG, Byrne BM, Groen A, Dankert J. Pretreatment methods prior to gas chromatographic analysis of volatile fatty acids from faecal samples. Clin Chim Acta 1977;78:243–50.
   PubMed Web of Science ®Google Scholar
• Schmidt DS. Molekulare Analyse des probiotischen Stamms Escherichia coli Nissle 1917. Dissertation, Technische Universität Dresden, 2009.
   Google Scholar
• Dobrindt U. (Patho)-Genomics of Escherichia coli. Int J Med Microbiol 2005;295:357–71.
   Web of Science ®Google Scholar
• Sun J, Gunzer F, Westendorf AM, Buer J, Scharfe M, Jarek M, . Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. J Biotechnol 2005;117:147–61.
   PubMed Web of Science ®Google Scholar
• Feldgarden M, Golden S, Wilson H, Riley MA. Can phage defence maintain colicin plasmids in Escherichia coli? Microbiology 1995;141:2977–84.
   Web of Science ®Google Scholar
• Reissbrodt R, Hammes WP, Dal Bello F, Prager R, Fruth A, Hantke K, . Inhibition of growth of Shiga toxin-producing Escherichia coli by nonpathogenic Escherichia coli. FEMS Microbiol Lett 2009;290:62–9.
   PubMed Web of Science ®Google Scholar
• Sonnenborn U, Greinwald R. 1991. Beziehungen zwischen Wirtsorganismus und Darmflora unter besonderer Berücksichtigung von Physiologie und Funktion der normalen Escherichia-coli-Flora. Stuttgart: Schattauer Verlag.
   Google Scholar
• Halbert SP. The antagonism of coliform bacteria against shigellae. J Immunol 1948;58:153–67.
   PubMed Web of Science ®Google Scholar
• Mayr-Harting A, Hedges AJ, Berkeley RCW. Methods for studying bacterocins. Methods Microbiol 1972;7a: 315–422.
   Google Scholar
• Denou E, Rezzonico E, Panoff JM, Arigoni F, Brüssow H. A mesocosm of Lactobacillus johnsonii, Bifidobacterium longum, and Escherichia coli in the mouse gut. DNA Cell Biol 2009;28:413–22.
   Web of Science ®Google Scholar
• Lorenz A, Schulze J. Establishment of E. coli Nissle 1917 and its interaction with Candida albicans in gnotobiotic rats. Microecol Ther 1996;24:45–51.
   Google Scholar
• Mandel L, Trebichavsky I, Splichal I, Schulze J. Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets. Mestecky J, Russell MW, Jackson S, Michalek SM, Tlaskalova-Hogenova H, Sterzl J. Advances in mucosal immunology. New York: Plenum Press. 1995. 463–4.
   Google Scholar
• Schulze J, Lorenz A, Mandel L. Colonisation of Escherichia coli in different gnotobiotic animal models. Microb Ecol Health Dis 1992;5:iv–v.
   Google Scholar
• Leatham MP, Banerjee S, Autieri SM, Mercado-Lubo R, Conway T, Cohen PS. Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine. Infect Immun 2009;77:2876–86.
   PubMed Web of Science ®Google Scholar
• Lodinova-Zadnikova R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 1997;71:224–32.
   PubMedGoogle Scholar
• Schröder H. Entwicklung der aeroben Darmflora bei Neugeborenen nach Kolonisierung mit dem E. coli-Stamm Nissle 1917. Der Kinderarzt 1992;23:1619–25.
   Google Scholar
• Swidsinski A, Swidsinski S, Godzun A, Orthner M, Lochs H. Therapy with E. coli Nissle reduces concentrations of mucosa associated colonic flora in patients with ulcerative colitis. Gastroenterology 2000;118:A1138.
   Web of Science ®Google Scholar
• Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, . The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 2004;40:223–9.
   PubMedGoogle Scholar
• Oelschlaeger TA, Altenhoefer A, Hacker J. Inhibition of Salmonella typhimurium invasion into intestinal cells by the probiotic E. coli strain Nissle 1917. Gastroenterology 2001; 120(5 Suppl 1):A-326.
   Web of Science ®Google Scholar
• Boudeau J, Glasser AL, Julien S, Colombel JF, DarfeuilleMichaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:45–56.
   PubMed Web of Science ®Google Scholar
• Duncker S. Auswirkung von oral verabreichtem Escherichia coli Nissle 1917 auf das Darm-assoziierte Immunsystem des Schweins. Dissertation, Tierärztl, Hochschule Hannover, 2005.
   Google Scholar
• Duncker SC, Lorentz A, Schroeder B, Breves G, Bischoff SC. Effect of orally administered probiotic E. coli strain Nissle 1917 on intestinal mucosal immune cells of healthy young pigs. Vet Immunol Immunopathol 2006;111:239–50.
   PubMed Web of Science ®Google Scholar
• Hockertz S. Immunmodulierende Wirkung von abgetöteten apathogenen Escherichia coli Stamm Nissle 1917 auf das Makrophagensystem. Arzneim-Forsch/Drug Res 1991;41:1108–12.
   Google Scholar
• Cross ML, Ganner A, Teilab D, Fray LM. Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria. FEMS Immunol Med Microbiol 2004;42:173–80.
   PubMed Web of Science ®Google Scholar
• Fink LN, Frokiaer H. Dendritic cells from Peyer's patches and mesenteric lymph nodes differ from spleen dendritic cells in their response to commensal gut bacteria. Scand J Immunol 2008;68:270–9.
   PubMed Web of Science ®Google Scholar
• Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, . Lactobacilli, bifidobacteria and E. coli Nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 2006;12:5978–86.
   PubMed Web of Science ®Google Scholar
• Kamada N, Maeda K, Inoue N, Hisamatsu T, Okamoto S, Hong KS, . Non-pathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect Immun 2008;76:214–20.
   PubMed Web of Science ®Google Scholar
• Krämer S, Sellge G, Lorentz A, Krueger D, Schemann M, Feilhauer K, . Selective activation of human intestinal mast cells by Escherichia coli hemolysin. J Immunol 2008;181:1438–45.
   PubMed Web of Science ®Google Scholar
• Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286:G613–26.
   PubMed Web of Science ®Google Scholar
• Rasche C, Wolfram C, Wahls M, Worm M. Differential immunomodulating effects of inactivated probiotic bacteria on the allergic immune response. Acta Derm Venereol 2007;87:305–11.
   PubMed Web of Science ®Google Scholar
• Sturm A, Rilling K, Baumgart DC, Gargas K, AbouGhazale T, Raupach B, . Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005;73:1452–65.
   PubMed Web of Science ®Google Scholar
• Ukena SN, Westendorf AM, Hansen W, Rohde M, Geffers R, Coldewey S, . The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1. BMC Med Genet 2005;6:1–13.
   Web of Science ®Google Scholar
• Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, . NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72:5750–8.
   PubMed Web of Science ®Google Scholar
• Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCZeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007;9:804–16.
   PubMed Web of Science ®Google Scholar
• Maeda K, Inoue N, Kamada N, Hong KS, Ogata H, Ishii H, . Non-pathogenic Escherichia coli inhibits signal transduction pathway in intestinal epithelia cells: a novel mechanism of action. Gastroenterology 2004;126(4 Suppl 2): A-577.
   Web of Science ®Google Scholar
• Otte JM, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr Cancer 2009;61:103–13.
   PubMed Web of Science ®Google Scholar
• Grabig A, Paclik D, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, . Escherichia coli strain Nissle 1917 ameliorates experimental colitis via Toll-like receptor 2- and Tolllike receptor 4-dependent pathways. Infect Immun 2006;74:4075–82.
   PubMed Web of Science ®Google Scholar
• Guzy C, Paclik D, Schirbel A, Sonnenborn U, Wiedenmann B, Sturm A. The probiotic Escherichia coli strain Nissle 1917 induces gammadelta T cell apoptosis via caspase- and FasL-dependent pathways. Int Immunol 2008;20:829–40.
   PubMed Web of Science ®Google Scholar
• Trebichavsky I, Cukrowska B, Kozakova H, Schulze J, Rehakova Z, Sinkora J, . Association of germ-free piglets with two non-pathogenic E. coli strains: Nissle 1917 stimulates the immune system more than O86 strain. J Mol Med 1998;76:B-9.
   Google Scholar
• Lodinová-Zádníková R, Tlaskalová-Hogenová H, Sonnen-born U. Local and serum antibody response in fullterm and premature infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (Mutaflor). Pediatr Allergy Immunol 1992;3:43–8.
   Google Scholar
• Cukrowska B, Lodinová-Zádníková R, Enders C, Sonnen-born U, Schulze J, Tlaskalová-Hogenová H. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002;55:204–9.
   PubMed Web of Science ®Google Scholar
• Bohn E, Bechtold O, Zahir N, Frick JS, Reimann J, Jilge B, . Host gene expression in the colon of gnotobiotic interleukin-2-deficient mice colonized with commensal colitogenic or noncolitogenic bacterial strains: common patterns and bacteria strain specific signatures. Inflamm Bowel Dis 2006;12:853–62.
   Web of Science ®Google Scholar
• Waidmann M, Bechtold O, Frick JS, Lehr HA, Schubert S, Dobrindt U, . Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 2003;125:162–77.
   PubMed Web of Science ®Google Scholar
• Arribas B, Rodriguez-Cabezas ME, Camuesco D, Comalada M, Ballon E, Utrilla P, . A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol 2009;157:1024–33.
   PubMed Web of Science ®Google Scholar
• Hudcovic T, Stepankova R, Kozakova H, Hrncir T, Tlaskalova-Hogenova H. Effects of monocolonization with Escherichia coli strains O6K13 and Nissle 1917 on the development of experimentally induced acute and chronic intestinal inflammation in germ-free immunocompetent and immunodeficient mice. Folia Microbiol 2007;52:618–26.
   Web of Science ®Google Scholar
• Kamada N, Inoue N, Hisamatsu T, Okamoto S, Matsuoka K, Sato T, . Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 2005;11:455–63.
   PubMed Web of Science ®Google Scholar
• Kokesova A, Frolova L, Kverka M, Sokol D, Rossmann P, Bartova J, . Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol 2006;51:478–84.
   PubMed Web of Science ®Google Scholar
• Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Göttl C, . Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004;11:372–8.
   PubMedGoogle Scholar
• Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, . Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
   PubMed Web of Science ®Google Scholar
• Bickert T, Trujillo-Vargas CM, Duechs M, Wohlleben G, Polte T, Hansen G, . Probiotic Escherichia coli Nissle 1917 suppresses allergen-induced Th2 responses in the airways. Int Arch Allergy Immunol 2009;149:219–30.
   PubMed Web of Science ®Google Scholar
• Hockertz S. Augmentation of host defence against bacterial and fungal infections of mice pretreated with the non-pathogenic Escherichia coli strain Nissle 1917. Arzneim-Forsch/Drug Res 1997;47(I):793–6.
   Google Scholar
• Von Bünau R, Jaekel L, Schubotz E, Schwarz S, Stroff T, Krüger M. Escherichia coli strain Nissle 1917: significant reduction of neonatal calf diarrhea. J Dairy Sci 2005;88:317–23.
   Web of Science ®Google Scholar
• Clavel T, Haller D. Molecular interactions between bacteria, the epithelium, and the mucosal immune system in the intestinal tract: implications for chronic inflammation. Curr Issues Intest Microbiol 2007;8:25–43.
   PubMedGoogle Scholar
• Zoumpopoulou G, Tsakalidou E, Dewulf J, Pot B, Grangette C. Differential crosstalk between epithelial cells, dendritic cells and bacteria in a co-culture model. Int J Food Microbiol 2009;131:40–51.
   Web of Science ®Google Scholar
• Schultz M, Butt AG. Methodological aspects in probiotic research – a brief review with an emphasis on epithelial barrier function. Int J Probiotics Prebiotics 2007;2:85–96.
   Google Scholar
• Cichon C, Enders C, Sonnenborn U, Schmidt MA. DNA-microarray-based comparison of cellular responses in polarized T84 epithelial cells triggered by probiotics: E. coli Nissle 1917 (EcN) and Lactobacillus acidophilus PZ1041. Gastroenterology 2004;126(4 Suppl. 2):A-578–9.
   Google Scholar
• Wehkamp J, Harder J, Wehkamp-von Meissner B, Schwichtenberg L, Fellermann K, Herrlinger KR, . The probiotic E. coli Nissle 1917 (Mutaflor) induces defensins in intestinal epithelial cells: a novel mechanism of action. Gastroenterology 2002;122(4 Suppl):A75–6.
   Google Scholar
• Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin-2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007;75:2399–407.
   PubMed Web of Science ®Google Scholar
• Hafez M, Hayes K, Goldrick M, Warhurst G, Grencis R, Roberts IS. The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infect Immun 2009;77:2995–3003.
   PubMed Web of Science ®Google Scholar
• Konturek PC, Brzozowski TM, Burnat G, Pajdo R, Hahn EG, Konturek SJ. Protective effects of probiotic Echerichia coli Nissle 1917 (EcN) bacterial strain against stress-induced acute gastric mucosal lesions. Gastroenterology 2007;132(4 Suppl S1):A-411.
   Web of Science ®Google Scholar
• Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, . Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113–23.
   PubMedGoogle Scholar
• Kido J, Kido R, Fagerhol MK, Nagata T. Calprotectin release from human neutrophils is induced by Porphyromonas gingivalis lipopolysacccharide via the CD14-Toll-like receptor-nuclear factor kappaB pathway. J Period Res 2003;38:557–63.
   Web of Science ®Google Scholar
• Nisapakultorn K, Ross KF, Herzberg MC. Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect Immun 2001;69:3692–6.
   PubMed Web of Science ®Google Scholar
• Splichal I, Fagerhol MK, Trebichavsky I, Splichalova A, Schulze J. The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages. Immunobiology 2005;209:681–7.
   Web of Science ®Google Scholar
• Hooper LV, Gordon JI. Commensal host–bacterial relationships in the gut. Science 2001;292:1115–18.
   PubMed Web of Science ®Google Scholar
• Hord NG. Eukaryotic-microbiota crosstalk: potential mechanisms for health benefits of prebiotics and probiotics. Annu Rev Nutr 2008;28:215–31.
   PubMed Web of Science ®Google Scholar
• Horswill AR, Nauseef WM. Host interception of bacterial communication signals. Cell Host Microbe 2008;4:507–9.
   Web of Science ®Google Scholar
• Köhler H, McCormick BA, Walker WA. Bacterial–enterocyte crosstalk: cellular mechanisms in health and disease. J Pediatr Gastroenterol Nutr 2003;36:175–85.
   PubMed Web of Science ®Google Scholar
• Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol 2006;22:13–7.
   PubMed Web of Science ®Google Scholar
• Spiller RC. Postinfective bowel dysfunction. Curr Opin Gastroenterol 1997;13:85–9.
   Web of Science ®Google Scholar
• Liebregts T, Adam B, Bertel A, Jones S, Schulze J, Enders C, . Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model. Neurogastroenterol Motil 2005;17:410–14.
   PubMed Web of Science ®Google Scholar
• Bär F, von Koschitzky H, Roblick U, Bruch HP, Schulze L, Sonnenborn U, . Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009;21:559–66.
   Web of Science ®Google Scholar
• Goel A, Mittal A, Evstatiev R, Nemeth M, Kruis W, Stolte M, . In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis. Aliment Pharmacol Ther 2009;30:634–42.
   Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, . Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617–23.
   PubMed Web of Science ®Google Scholar
• Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res 1983;113:173–215.
   PubMed Web of Science ®Google Scholar
• Speit G, Hartmann A. The comet assay: a sensitive genotoxicity test for the detection of DNA damage. Methods Mol Biol 2005;291:85–95.
   PubMedGoogle Scholar
• Sonnenborn U, Janosch D, Dubbert S, Stroff T, Schulze L, Müller H. Antimutagenic activity of the probiotic E. coli strain Nissle 1917. J Crohn's Colitis 2009;3:136.
   Google Scholar
• Schultz M, Watzl S, Ölschläger T, Rath HC, Göttl C, Lehn N, . Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo. J Microbiol Methods 2005;61:389–98.
   PubMed Web of Science ®Google Scholar
• Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, . Intestinal immunity of Escherichia coli Nissle 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005;43:373–84.
   PubMed Web of Science ®Google Scholar
• Nagy G, Dobrindt U, Grozdanov L, Hacker J, Emödy L. Transcriptional regulation through RfaH contributes to intestinal colonization by Escherichia coli. FEMS Microbiol Lett 2005;244:173–80.
   PubMed Web of Science ®Google Scholar
• Monteiro C, Saxena I, Wang X, Kader A, Bokranz W, Simm R, . Characterization of cellulose production in Escherichia coli Nissle 1917 and its biological consequences. Environ Microbiol 2009;11:1105–16.
   PubMed Web of Science ®Google Scholar
• Brombacher E, Dorel C, Zehnder AJB, Landini P. The curli biosynthesis regulator CsgD co-ordinates the expression of both positive and negative determinants for biofilm formation in Escherichia coli. Microbiology 2003;149:2847–57.
   PubMed Web of Science ®Google Scholar
• Kuhnert P, Hacker J, Mühldorfer I, Burnens AP, Nicolet J, Frey J. Detection system for Escherichia coli-specific virulence genes: absence of virulence determinants in B and C strains. Appl Environ Microbiol 1997;63:703–9.
   Web of Science ®Google Scholar
• Ott M, Hoschützky H, Jann K, Van Die I, Hacker J. Gene clusters for S fimbrial adhesin (sfa) and F1C fimbriae (foc) of Escherichia coli: comparative aspects of structure and function. J Bacteriol 1988;170:3983–90.
   Web of Science ®Google Scholar
• Zingler G, Ott M, Blum G, Falkenhagen U, Naumann G, Sokolowska-Köhler W, . Clonal analysis of Escherichia coli serotype O6 strains from urinary tract infections. Microb Pathog 1992;12:299–310.
   Web of Science ®Google Scholar
• Zingler G, Blum G, Falkenhagen U, Orskov I, Orskov F, Hacker J, . Clonal differentiation of uropathogenic Escherichia coli isolates of serotype O6:K5 by fimbrial antigen typing and DNA long-range mapping techniques. Med Microbiol Immunol 1993;182:13–24.
   Web of Science ®Google Scholar
• Valdebenito M, Crumbliss AL, Winkelmann G, Hantke K. Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. Int J Med Microbiol 2006;296:513–20.
   PubMed Web of Science ®Google Scholar
• Malchow H, Sonnenborn U, Greinwald R, Körner A. Colonization of adults by an apathogenic E. coli strain administered after gut decontamination. Gastroenterology 1995; 108:A-869.
   Web of Science ®Google Scholar
• Jöres-Nguyen-Xuan TH, Boehm SK, Joeres L, Schulze J, Kruis W. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflamm Bowel Dis 2009 July 27 [Epub ahead of print].
   Google Scholar
• Prilassnig M, Wenisch C, Daxboeck F, Feierl G. Are probiotics detectable in human feces after oral uptake by healthy volunteers? Wien Klin Wochenschr 2007;119:1–7.
   Web of Science ®Google Scholar
• Bernardeau M, Guguen M, Vernoux JP. Beneficial lactobacilli in food and feed: long-term use, biodiversity and proposals for specific and realistic safety assessments. FEMS Microbiol Rev 2006;30:487–513.
   PubMed Web of Science ®Google Scholar
• Besselink MGH, van Santvoort HC, Buskens E, Boer-meester MA, van Goor H, Timmerman HM, . Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:651–9.
   PubMed Web of Science ®Google Scholar
• Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006;83:1256–64.
   PubMed Web of Science ®Google Scholar
• Ezendam J, Van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev 2006;64:1–14.
   PubMed Web of Science ®Google Scholar
• Mattia A, Merker R. Regulation of probiotic substances as ingredients in foods: premarket approval or “generally recognized as safe” notification. Clin Infect Dis 2008;46(Suppl 2): 115–8.
   Web of Science ®Google Scholar
• Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46(Suppl 2):104–11.
   PubMed Web of Science ®Google Scholar
• Vankerckhoven V, Huys G, Vancanneyt M, Vael C, Klare I, Romond M-B, . Biosafety assessment of probiotics used for human consumption: recommendations from the EUPROSAFE project. Trends Food Sci Tech 2008;19:102–14.
   Web of Science ®Google Scholar
• Wassenaar TM, Klein G. Safety aspects and implications of regulation of probiotic bacteria in food and food supplements. J Food Protect 2008;71:1734–41.
   PubMed Web of Science ®Google Scholar
• Blum G, Falbo V, Caprioli A, Hacker J. Gene clusters encoding the cytotoxic necrotizing factor type 1, Prsfimbriae and alpha-hemolysin form the pathogenicity island II of the uropathogenic Escherichia coli strain J96. FEMS Microbiol Lett 1995;126:189–95.
   PubMed Web of Science ®Google Scholar
• Evans DJJr, Evans DG. Classification of pathogenic Escherichia coli according to serotype and the production of virulence factors, with special reference to colonization-factor antigens. Rev Infect Dis 1983;5(Suppl 4):S692–701.
   Google Scholar
• Levine MM. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987;155:377–89.
   PubMed Web of Science ®Google Scholar
• Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142–201.
   PubMed Web of Science ®Google Scholar
• Orskov I, Orskov F. Escherichia coli in extra-intestinal infections. J Hyg 1985;95:551–75.
   PubMedGoogle Scholar
• Karch H, Meyer T. Evaluation of oligonucleotide probes for identification of Shiga-like-toxin-producing Escherichia coli. J Clin Microbiol 1989;27:1180–6.
   PubMed Web of Science ®Google Scholar
• Mandel L, Travnicek J. The minipig as a model in gnotobiology. Die Nahrung 1987;31:613–17.
   Google Scholar
• Sereny B. Experimental keratoconjunctivitis Shigellosa. Acta Microbiol Hung 1957;4:367–76.
   Google Scholar
• Beutin L, Gleier K, Kontny I, Echeverria P, Scheutz F. Origin and characteristics of enteroinvasive strains of Escherichia coli (EIEC) isolated in Germany. Epidemiol Infect 1997;118:199–205.
   Web of Science ®Google Scholar
• Small PLC, Isberg RR, Falkow S. Comparison of the ability of enteroinvasive Escherichia coli, Salmonella typhimurium, Yers-inia pseudotuberculosis, and Yersinia enterocolitica to enter and replicate within Hep-2-cells. Infect Immun 1987;55:1674–9.
   PubMed Web of Science ®Google Scholar
• Tröger H, Richter J, Beutin L, Epple HJ, Fromm M, Zeitz M, . Wege der bakteriellen Translokation in Kolon-Epithelzellen unter dem Einfluss pro-inflammatorischer Zytokine. Z Gastroenterol 2003;41:771.
   Google Scholar
• Reeves P. Role of O-antigen variation in the immune response. Trends Microbiol 1995;3:381–6.
   PubMed Web of Science ®Google Scholar
• Cassels FJ, Wolf MK. Colonization factors of diarrheagenic E. coli and their intestinal receptors. J Ind Microbiol 1995;15:214–26.
   PubMedGoogle Scholar
• Zingler G, Schmidt G, Orskov I, Orskov F, Falkenhagen U, Naumann G. K-antigen identification, hemolysin production, and hemagglutination types of Escherichia coli O6 strains isolated from patients with urinary tract infections. Zbl Bakt 1990;274:372–81.
   Google Scholar
• Gaastra W, Svennerholm AM. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 1996;4:444–52.
   PubMed Web of Science ®Google Scholar
• Klemm P. Fimbrial adhesins of Escherichia coli. Rev Infect Dis 1985;7:321–40.
   PubMedGoogle Scholar
• Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991;4:80–128.
   PubMed Web of Science ®Google Scholar
• Marre R, Hacker J, Henkel W, Goebel W. Contribution of cloned virulence factors from uropathogenic Escherichia coli strains to nephropathogenicity in an experimental rat pyelonephritis model. Infect Immun 1986;54:761–7.
   Web of Science ®Google Scholar
• NCCLS(National Committee for Clinical Laboratory Standards). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th edn. Approved standard M7–A4. 1997.
   Google Scholar
• Frick JS, Zahir N, Kirschning C, Bohn E, Autenrieth IB. Commensal bacteria differentially modulate cytokine expression in dendritic cells. Int J Med Microbiol 2005;295:131.
   Google Scholar
• Bleich A, Sundberg JP, Smoczek A, Von Wasielewski R, De Buhr MF, Janus LM, . Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. Int J Exp Pathol 2008;89:45–54.
   Web of Science ®Google Scholar
• Burmeister M, Ulanovsky L. 1992. Pulsed-field gel electrophoresis; protocols, methods, and theories. Totowa, NJ: Humana Press.
   Google Scholar
• Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991;19:6823–31.
   PubMed Web of Science ®Google Scholar
• Hardy KG. 1987. Plasmids – a practical approach. Washington, DC: IRL Press.
   Google Scholar
• Oswald S. Einführung von Virulenz-assoziierten Antigenen in den Escherichia coli-Carrier-Stamm DSM 6601. Dissertation, Bayr.Julius-Maximilians-Universität Würzburg, 1997.
   Google Scholar
• Datz M, Janetzki-Mittmann C, Franke S, Gunzer F, Schmidt H, Karch H. Analysis of the enterohemorrhagic Escherichia coli O157 DNA region containing lambdoid phage gene P and Shiga-like toxin structural genes. Appl Environ Micro-biol 1996;62:791–7.
   Web of Science ®Google Scholar
• Magistrelli C, Colombo E, Tognoni A, Grandi G. Transfection of E. coli with lambda DNA by electroporation. Micro-biologica 1992;15:397–8.
   Google Scholar
• Smith HW, Green P, Parsell Z. Vero cell toxins in Escherichia coli and related bacteria: transfer by phage and conjugation and toxic action in laboratory animals, chickens, and pigs. J Gen Microbiol 1983;129:3121–37.
   Google Scholar
• Krammer HJ, Schlieger F, Harder H, Franke A, Singer MV. Probiotika in der Therapie des Reizdarmsyndroms. Z Gastroenterol 2005;43:467–71.
   Web of Science ®Google Scholar
• Kruis W, Chrubasik S, Stange C, Schulze J. Therapeutische Wirksamkeit des probiotischen E. coli-Stammes Nissle 1917 bei Reizdarm-Subgruppen. Z Gastroenterol 2004;42:785.
   Google Scholar
• Plaßmann D, Schulte-Witte H. Therapie des Reizdarmsyndroms mit Escherichia coli Stamm Nissle 1917 (EcN). Eine retrospektive Untersuchung. Med Klin 2007;102:888–92.
   Google Scholar
• Tromm A, Niewerth U, Khoury M, Baestlein E, Wilhelms G, Schulze J, . The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. Z Gastroenterol 2004;42:365–9.
   PubMed Web of Science ®Google Scholar
• Goerg KJ, Schlörer E. Probiotische Therapie einer pseudomembranösen Kolitis. Dtsch Med Wochenschr 1998;123:1274–8.
   Web of Science ®Google Scholar
• Goerg KJ, Wybierala M, Rauen-Vossloh J, Hader C. A new approach in pseudomembranous colitis: probiotic Escherichia coli Nissle 1917 after intestinal lavage. Eur J Gastroenterol Hepatol 2008;20:155–6.
   Web of Science ®Google Scholar
• Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Treatment of mild to moderate acute attacks of distal ulcerative colitis with rectally-administered E. coli Nissle 1917: dose-dependent efficacy. Gastroenterology 2006;130(4 Suppl 2):A-119.
   Web of Science ®Google Scholar
• Malchow H. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653–8.
   Google Scholar
• Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003;15:313–15.
   PubMed Web of Science ®Google Scholar
• Kuzela L, Kascak M, Vavrecka A. Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 2001;96:3218–19.
   Web of Science ®Google Scholar
• Henker J, Schuster F, Nissler K. Successful treatment of gut-caused halitosis with a suspension of living non-pathogenic Escherichia coli bacteria – a case report. Eur J Pediatr 2001;160:592–4.
   PubMed Web of Science ®Google Scholar
• Lata J, Novotny I, Pribramska V, Jurankova J, Fric P, Kroupa R, . The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007;19:1111–3.
   PubMed Web of Science ®Google Scholar
• Wurzel RM. Prophylaxe der polymorphen Lichtdermatose. Aktuel Dermatol 1999;25:329–33.
   Google Scholar
• Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 2003;38(Suppl 15): 36–42.
   Google Scholar
• Loftus EVJr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504–17.
   PubMed Web of Science ®Google Scholar
• Mathew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 2004;13:R161–8.
   PubMed Web of Science ®Google Scholar
• Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmunity Reviews 2004;3:394–400.
   PubMed Web of Science ®Google Scholar
• Mahida YR, Rolfe VE. Host–bacterial interactions in inflammatory bowel disease. Clin Sci 2004;107:331–41.
   Web of Science ®Google Scholar
• Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9:93–103.
   PubMed Web of Science ®Google Scholar
• Böhm SK, Kruis W. Probiotics. Do they help to control intestinal inflammation?Domschke WW, Kagnoff MF, Kucharzik TF, Mayer LF, Targan SR. Inflammatory bowel disease. Genetics, barrier function, immunologic mechanisms, and microbial pathways. Ann N Y Acad Sci 2006;1072:339–50.
   Web of Science ®Google Scholar
• Duchmann R. The role of probiotics and antibiotics in regulating mucosal inflammation. Neurath MF, Blum-berg RS. Immune mechanisms in inflammatory bowel disease. Advances in Experimental Medicine and Biology, 579. Berlin: Springer Science. 2006.219–26.
   Google Scholar
• Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 2006;12:5941–50.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2008. J Clin Gastroenterol 2008;42(Suppl 2):S97–103.
   Web of Science ®Google Scholar
• Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr Treat Options Gastroenterol 2003;6:283–8.
   Google Scholar
• Floch MH, Montrose DC. Use of probiotics in humans: an analysis of the literature. Gastroenterol Clin North Am 2005;34:547–70.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, . Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 2006;12:3306–13.
   PubMed Web of Science ®Google Scholar
• Jones JL, Foxx-Orenstein AE. Probiotics in inflammatory bowel disease. Pract Gastroenterol 2006;30:44–50.
   Google Scholar
• Kligler B, Hanaway P, Cohrssen A. Probiotics in children. Pediatr Clin North Am 2007;54:949–67.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Farrell RJ. Probiotics and inflammatory bowel disease. BioDrugs 2003;17:179–86.
   PubMed Web of Science ®Google Scholar
• Marteau P, Seksik P, Jian R. Probiotics and intestinal health effects: a clinical perspective. Br J Nutr 2002;88(Suppl 1): S51–7.
   Web of Science ®Google Scholar
• Marteau P, Seksik P, Jian R. Probiotics and health: new facts and ideas. Curr Opin Biotechnol 2002;13:486–9.
   Web of Science ®Google Scholar
• Sartor RB. Therapeutic manipulation of the enteric micro-flora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620–33.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577–94.
   PubMed Web of Science ®Google Scholar
• Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853–8.
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635–9.
   PubMed Web of Science ®Google Scholar
• Burke DA, Axon ATR. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988;297:102–4.
   PubMed Web of Science ®Google Scholar
• Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, . Diagnostik und Therapie der Colitis Ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen zusammen mit dem Kompeten-znetz chronisch entzündliche Darmerkrankungen. Z Gastroenterol 2004;42:979–83.
   PubMed Web of Science ®Google Scholar
• Stange EF, Riemann J, Von Herbay A, Lochs H, Fleig WE, Schölmerich J, . Diagnostik und Therapie der Colitis ulcerosa - Ergebnisse einer evidenzbasierten Konsensuskon-ferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Leitlinien der DGVS. Z Gastro-enterol 2001;39:19–72.
   Web of Science ®Google Scholar
• Travis SPL, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008;2:24–62.
   Google Scholar
• Vogelsang H, Tilg H, Petritsch W, Knoflach P. Colitis ulce-rosa: medikamentöse Rezidivprophylaxe. Österreichische Ärztezeitung 2003;1/2:40–1.
   Google Scholar
• Henker J, Müller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 2008;46:874–5.
   PubMed Web of Science ®Google Scholar
• Bruckschen E, Horosiewicz H. Chronische Obstipation, Vergleich von mikrobiologischer Therapie und Lactulose. Münch Med Wochenschr 1994;16:241–5.
   Google Scholar
• Möllenbrink M, Bruckschen E. Behandlung der chronischen Obstipation mit physiologischen Escherichia-coli-Bakterien. Med Klin 1994;89:587–93.
   Google Scholar
• Hernando-Harder AC, Von Bünau R, Nadarajah M, Singer MV, Harder H. Influence of E. coli Strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation. Dig Dis Sci 2008;53:443–50.
   Web of Science ®Google Scholar
• Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, . The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007;166:311–8.
   PubMed Web of Science ®Google Scholar
• Henker J, Laass MW, Blokhin BM, Maydannik VG, Bolbot YK, Elze M, . Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 2008;27:494–9.
   Web of Science ®Google Scholar
• Fuller R. History and development of probiotics. 1992. Fuller R. Probiotics. London: Champman & Hall. 1–8.
   Google Scholar
• Bendali F, Sanaa M, Bichet H, Schelcher F. Risk factors associated with diarrhoea in newborn calves. Vet Res 1999;30:509–22.
   PubMed Web of Science ®Google Scholar
• Schroeder B, Duncker S, Barth S, Bauerfeind R, Gruber AD, Deppenmeier S, . Preventive effects of the probiotic Escherichia coli strain Nissle 1917 on acute secretory diarrhea in a pig model of intestinal infection. Dig Dis Sci 2006;51:724–31.
   PubMed Web of Science ®Google Scholar
• Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev 2003;8:143–55.
   PubMedGoogle Scholar
• Autieri SM, Lins JJ, Leatham MP, Laux DC, Conway T, Cohen PS. L-fucose stimulates utilization of D-ribose by Escherichia coli MG1655 (Delta)fucAO and E. coli Nissle 1917 (delta)fucAO mutants in the mouse intestine and in M9 minimal medium. Infect Immun 2007;75:5465–75.
   PubMed Web of Science ®Google Scholar
• Brader P, Stritzker J, Riedl CC, Zanzonico P, Cai S, Burnazi EM, . Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin Cancer Res 2008;14:2295–302.
   PubMed Web of Science ®Google Scholar
• Coldewey SM, Hartmann M, Schmidt DS, Engelking U, Ukena S, Gunzer F. Impact of the rpoS genotype for acid resistance patterns of pathogenic and probiotic Escherichia coli. BMC Microbiol 2007;7:21.
   Web of Science ®Google Scholar
• Hejnova J, Pages D, Rusniok C, Glaser P, Sebo P, Buchrieser C. Specific regions of genome plasticity and genetic diversity of the commensal Escherichia coli A0 34/86. Int J Med Microbiol 2006;296:541–6.
   Web of Science ®Google Scholar
• Mundy R, Girard F, FitzGerald AJ, Frankel G. Comparison of colonization dynamics and pathology of mice infected with enteropathogenic Escherichia coli, enterohaemorrhagic E. coli and Citrobacter rodentium. FEMS Microbiol Lett 2006;265:126–32.
   Web of Science ®Google Scholar
• Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 2007;297:151–62.
   PubMed Web of Science ®Google Scholar
• Duan F, March JC. Interrupting Vibrio cholerae infection of human epithelial cells with engineered commensal bacterial signaling. Biotechnol Bioeng 2008;101:128–34.
   Web of Science ®Google Scholar
• Duan F, Curtis KL, March JC. Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. Appl Environ Microbiol 2008;74:7437–8.
   Web of Science ®Google Scholar
• Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, . Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A 2005;102:1993–8.
   Web of Science ®Google Scholar
• Remer KA, Bartrow M, Roeger B, Moll H, Sonnenborn U, Oelschlaeger TA. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88. Int J Med Microbiol 2009;299:467–78.
   PubMed Web of Science ®Google Scholar
• Buddenborg C, Daudel D, Liebrecht S, Greune L, Humberg V, Schmidt MA. Development of a tripartite vector system for live oral immunization using a Gram-negative probiotic carrier. Int J Med Microbiol 2008;298:105–14.
   PubMed Web of Science ®Google Scholar